The Know AML website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and Know AML cannot guarantee the accuracy of translated content. Know AML and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
What options are there for patients with the SRSF2 mutation?
Gail Roboz
November 6, 2020
During Blood Cancer Awareness Month, Know AML spoke to Gail Roboz, a world-leading doctor in acute myeloid leukemia who is based at Weill Cornell Medicine, New York, US. We asked, "What options are there for patients with the SRSF2 mutation?" In this video, Gail explains that although SRSF2 mutations are not uncommon in acute myeloid leukemia, there are no specific trials investigating this. However, there are some ongoing trials targeting the spliceosome.
To what extent do you agree with the following statements?
Please rate between 1 and 5, with 1 being 'strongly disagree' and 5 being 'strongly agree'.
